Evelo Biosciences, Inc. Common Stock
EVLO
EVLO was delisted on the 11th of December, 2023.
37 hedge funds and large institutions have $329M invested in Evelo Biosciences, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 20 increasing their positions, 7 reducing their positions, and 7 closing their positions.
186% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 7
6% more capital invested
Capital invested by funds: $312M → $329M (+$17.5M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
14% less funds holding
Funds holding: 43 → 37 (-6)
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$5.86M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.26M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$1.44M |
| 4 |
State Street
Boston,
Massachusetts
|
+$697K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$512K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
-$1.77M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$605K |
| 3 |
DIM
DC Investments Management
Mclean,
Virginia
|
-$436K |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$397K |
| 5 |
Goldman Sachs
New York
|
-$298K |
EVLO Hedge Fund Activity: Q3 2018 in Review
37 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Evelo Biosciences, Inc. Common Stock (EVLO) for Q3 2018, worth a combined $329M — up 5.6% from $312M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of EVLO and 1 opened new positions — a net loss of 6 holders — while 7 trimmed existing stakes and 20 added.
The largest buyer was Credit Suisse, adding an estimated $5.86M. The largest seller was Laurion Capital Management, exiting entirely with an estimated $1.77M sold.
- 37 institutional investors held Evelo Biosciences, Inc. Common Stock (EVLO) as of Q3 2018, down from 43 in Q2 2018.
- Funds reported $329M of Evelo Biosciences, Inc. Common Stock stock for Q3 2018, up 5.6% quarter-over-quarter.
- 1 fund opened new Evelo Biosciences, Inc. Common Stock positions in Q3 2018 and 7 closed out, a net change of -6 holders.
- The largest Evelo Biosciences, Inc. Common Stock buyer in Q3 2018 was Credit Suisse, an estimated $5.86M added.
- The largest Evelo Biosciences, Inc. Common Stock seller in Q3 2018 was Laurion Capital Management, an estimated $1.77M sold.
Based on aggregated 13F filings for Q3 2018.